Absci (ABSI) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed Septerna (SEPN) over the past year, gaining 146.5% versus a gain of 71.3%. Septerna is the larger company by market cap ($1.63 billion vs $1.54 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | SEPN |
|---|---|---|
| Share price | $8.98 | $34.87 |
| Market cap | $1.54B | $1.63B |
| 1-day change | -2.66% | -3.15% |
| YTD return | +164.18% | +29.12% |
| 1-year return | +146.52% | +71.35% |
| 5-year return | -13.26% | — |
| EPS (TTM) | $-0.79 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $51.10 |
| 52-week low | $2.24 | $17.55 |
| Distance from 52-week high | -25.55% | -31.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +60.45% | +55.51% |
| Average volume | 3.45M | 393.97K |
| Shares outstanding | 171.61M | 46.68M |
| Employees | 140 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed SEPN by 75.2 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
ABSI vs SEPN FAQ
Which is bigger, Absci or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.63B compared with $1.54B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or SEPN?
ABSI returned +146.52% over the past 12 months, compared with +71.35% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Septerna in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Septerna.